Cue Biopharma, Inc. (CUE)

Market Cap	69.60M +49.7%
Revenue (ttm)	32.73M +309.6%
Net Income	-19.52M
EPS	-5.22
Shares Out	3.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,674
Open	23.26
Previous Close	23.01
Day's Range	21.02 - 24.35
52-Week Range	4.97 - 41.42
Beta	2.39
Analysts	Strong Buy
Price Target	115.00 (+437.89%)
Earnings Date	May 14, 2026

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE
• Website: https://www.cuebiopharma.com

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.

Analyst Summary

According to one analyst, the rating for CUE stock is "Strong Buy" and the 12-month stock price target is $115.0.

Price Target

$115.0

(437.89% upside)

Analyst Consensus: Strong Buy